Observational Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 6, 2023; 11(31): 7610-7618
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7610
Efficacy of β2-adrenergic receptor agonist combined with corticosteroid in the treatment of children with cough variant asthma
Jun-Yi Cao, Ying-Chun Wang, Xiao-Xia Deng
Jun-Yi Cao, Ying-Chun Wang, Department of Pediatrics, The First People's Hospital of Jiangxia District, Wuhan 430200, Hubei Province, China
Xiao-Xia Deng, Department of Pediatric Respiratory, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430070, Hubei Province, China
Co-first authors: Jun-Yi Cao and Ying-Chun Wang.
Author contributions: Cao JY, and Wang YC designed the research; Deng XX performed the research; Deng XX contributed new reagents/analytic tools; Cao JY, Wang YC, and Deng XX analyzed the data; Cao JY, and Wang YC wrote the paper. Cao JY and Ying-Chun Wang contributed equally to this work as co-first authors equally to this work. The reasons for designating Cao JY and Wang YC as co-first authors are threefold. First, the research was performed as a collaborative effort, and the designation of co-first authors authorship accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. This also ensures effective communication and management of post-submission matters, ultimately enhancing the paper's quality and reliability. Second, the overall research team encompassed authors with a variety of expertise and skills from different fields, and the designation of co-first authors best reflects this diversity. This also promotes the most comprehensive and in-depth examination of the research topic, ultimately enriching readers' understanding by offering various expert perspectives. Third, Cao JY and Wang YC contributed efforts of equal substance throughout the research process. The choice of these researchers as co-first authors acknowledges and respects this equal contribution, while recognizing the spirit of teamwork and collaboration of this study. In summary, we believe that designating Cao JY and Wang YC as co-first authors of is fitting for our manuscript as it accurately reflects our team's collaborative spirit, equal contributions, and diversity.
Institutional review board statement: The study was reviewed and approved by the first People's Hospital of Jiangxia District.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Xia Deng, MB, Nurse in charge, Department of Pediatric Respiratory, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, No. 745 Wuluo Road, Hongshan District, Wuhan 430070, Hubei Province, China. dengxiaoxia906@163.com
Received: September 19, 2023
Peer-review started: September 19, 2023
First decision: September 28, 2023
Revised: October 7, 2023
Accepted: October 26, 2023
Article in press: October 26, 2023
Published online: November 6, 2023
Processing time: 48 Days and 0.7 Hours
Abstract
BACKGROUND

Cough variant asthma (CVA) is one of the most common respiratory diseases in children, which has a serious impact on the quality of life and daily activities of children. For severe CVA, immunomodulatory drugs are needed.

AIM

To evaluate the efficacy of salmeterol combined with budesonide in the treatment of pediatric CVA.

METHODS

130 children with CVA from January 2020 to December 2022 were prospectively selected and randomly divided into an observation group (salmeterol combined with budesonide) and a control group (budesonide combined with a placebo). Compare the clinical efficacy of two groups before and after intervention. The evaluation parameters include cough frequency score, nocturnal cough arousal, and lung function indicators. Serum inflammatory markers, immune function markers and airway anatomical indicators were also measured.

RESULTS

After the intervention, the total effective rate of the observation group was significantly higher than that of the control group, and the cough frequency score and the night cough wake rate of the observation group were lower than that of the control group, with a statistically significant difference. In addition, the changes of lung function indicators, serum markers and immune function markers in the observation group were better than those in the control group.

CONCLUSION

The clinical efficacy of salmeterol combined with Budesonide in the treatment of CVA is better than that of Budesonide alone.

Keywords: Salmeterol; Budesonide; Cough variant asthma; Pediatrics; Efficacy analysis

Core Tip: Cough variant asthma (CVA) seriously affects children's daily activities and physical health. For severe CVA, immunomodulatory drugs are needed. The purpose of this study is to evaluate the efficacy of salmeterol combined with budesonide in the treatment of CVA in children. The results showed that after the intervention, the clinical symptoms of patients in the observation group were lighter and the level of immune markers was higher. The results of this study show that the combined treatment of the two drugs is better than budesonide alone.